The final part of the study of the new Russian drug pembrolizumab, which combats advanced forms of melanoma, has begun at the IM Sechenov First Moscow State Medical University. This drug is being developed as an alternative to the American immuno-oncology drug and is the result of the efforts of the R-Pharm group of companies within the scope of import substitution. The first two phases of the clinical trial showed good results in terms of safety and tolerability of the drug, which allowed us to proceed to the final phase.
The final study phase will include 300 participants divided into two groups. One group will be given the Russian drug, the other – the American analogue. The treatment will last two years, but the first results on evaluating the effectiveness of the drug will be available within six months after the start of the study.
The drug pembrolizumab opens up new possibilities in treating melanoma because it activates the body’s immune system to fight the tumor. According to Marina Sekacheva, Doctor of Medical Sciences, director of the Institute of Personalized Oncology at Sechenov University, these drugs can enable patients with advanced melanoma to fully recover in 30% of cases, which was almost impossible before.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
